AMPE News and Press, Ampio Pharmaceuticals Inc. From 06/17/21

Ampio Pharmaceuticals ([[AMPE]] +1.4%) posts newly integrated data from four of its earlier clinical trials utilizing the company's Ampion treatment for treating osteoarthritis of the knee ((OAK)).The pooled data showed a reduction in pain of 34.3% at two weeks (compared to 28.6% fo...

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK New integrated analysis reinforces Ampion's position as the first novel therapy to demonstrate clinical efficacy over saline for pati...

3 Penny Stocks For Your June 2021 Watchlist As vaccine rates around the world continue to spike, many believe that penny stocks could benefit from the end of the pandemic. Of course, penny stocks are not the only securities that will see improvements in financials in the coming mont...

Ampio Pharmaceuticals (AMPE) soars 33% premarket after receiving regulatory approval to expand enrollment of its AP-019 Phase II study to India.The study will utilize inhaled Ampion to treat people suffering from respiratory distress due to COVID-19. Due to the ongoing pol...

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India PR Newswire ENGLEWOOD, Colo. , June 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement...

Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo The Company's work amid the COVID-19 pandemic will be showcased to pharmaceutical and biopharmaceutical professionals working in drug manufacturing, supply cha...

Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium PR Newswire ENGLEWOOD, Colo. , June 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focu...

Ampio has existed for over a decade, and run more than a dozen trials for lead asset Ampion. Regulatory path is still unclear for osteoarthritis of the knee. Its COVID-19 program is probably more promising. For further details see: Ampio Pharmaceuticals: Regulatory Proce...

Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress The company's findings will be showcased to over 400 clinicians, respiratory health and critical care professionals, aerosol scientists, engineers, pr...

Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018) An estimated 3 to 10 million patients in the USA exhibit debilitating symptoms of Post-Acute Sequelae of SARS-CoV-2 PR Newswire ENGLEWOOD, Colo. , ...